PharmaShots Weekly Snapshots (February 07-11, 2022)
Published: Feb 11, 2022 | Tags: Nykode, VB10.16, Atezolizumab, P-II Trial, Advanced Cervical Cancer
GSK’s Benlysta (belimumab) Receives the NMPA’s Approval for the Treatment of Active Lupus Nephritis
Published: Feb 11, 2022 | Tags: GSK, Benlysta, belimumab, NMPA, Approval, Active Lupus Nephritis
Published: Feb 11, 2022 | Tags: Genentech, Vabysmo, Susvimo, P-III, YOSEMITE/ RHINE/ Archway Studies, DME, AMD
Published: Feb 11, 2022 | Tags: Novavax, NVX-CoV2373, Pediatric Population, P-III, PREVENT-19 Trial, COVID-19
Published: Feb 11, 2022 | Tags: Scynexis, Ibrexafungerp, P-III, CANDLE Study, Recurrent, Vaginal Yeast Infections
Published: Feb 11, 2022 | Tags: ObsEva, Theramex, Linzagolix, Uterine Fibroids, Endometriosis
Published: Feb 10, 2022 | Tags: SaNOtize, Nitric Oxide Nasal Spray, P-III Clinical Trial, COVID-19
Published: Feb 10, 2022 | Tags: Eli Lilly, Foundation Medicine, FoundationOne CDx, FoundationOne Liquid CDx, Retevmo Cancer
Published: Feb 10, 2022 | Tags: Regeneron, US, FDA, sBLA, Priority Review, Dupixent, dupilumab, Atopic Dermatitis
Published: Feb 10, 2022 | Tags: enGene, EG-70, P-I/II, LEGEND Trial, Non-Muscle Invasive Bladder Cancer
Published: Feb 10, 2022 | Tags: AKSO, Huadong Medicine, AB002, Solid Tumors, Asia
Published: Feb 10, 2022 | Tags: AiCuris, Hybridize, RNA-Based Therapy, BK Virus
Published: Feb 09, 2022 | Tags: Secura Bio, P-II, PRIMO Study, Copiktra, duvelisib, Peripheral T-cell Lymphoma
Published: Feb 09, 2022 | Tags: EdiGene, Neukio, iPSC-NK, Immune Cell Therapies, Solid Tumors
Published: Feb 09, 2022 | Tags: Bausch Health, Trulance, plecanatide, Health Canada, Approval, Irritable Bowel Syndrome, Constipation
Published: Feb 09, 2022 | Tags: Alkermes, Lybalvi, P-IIIb, ENLIGHTEN-Early Study, Schizophrenia, Bipolar I Disorder
Published: Feb 09, 2022 | Tags: Karyopharm, Selinexor, P-III, SIENDO Study, Endometrial Cancer
Healx Collaborated with Ovid to Develop and Commercialize Gaboxadol for Fragile X Syndrome
Published: Feb 09, 2022 | Tags: Healx, Ovid, Gaboxadol, Fragile X Syndrome
Published: Feb 08, 2022 | Tags: uniQure, AMT-130, P-Ib/II Trial, Huntington’s Disease
Published: Feb 08, 2022 | Tags: Sangamo, ST-920, P- I/II, STAAR Study, Fabry Disease, WORLDSymposium, 2022
Published: Feb 08, 2022 | Tags: NGM Bio, NGM621, US, FDA, Fast Track Designation, Geographic Atrophy, Age-Related Macular Degeneration
Published: Feb 08, 2022 | Tags: Actuate Therapeutics, Elraglusib, Folfirinox, Advanced, Pancreatic Cancer
RedHill Biopharma Reports Results of Opaganib in P-II/III Study for the Treatment of Severe COVID-19
Published: Feb 08, 2022 | Tags: RedHill Biopharma, Opaganib, P-II/III Study, Severe COVID-19
Published: Feb 08, 2022 | Tags: Astellas, AT845, P-I/II, FORTIS Trial, Late-Onset Pompe Disease, WORLDSymposium 2022
Published: Feb 07, 2022 | Tags: Active Biotech, P-Ib/IIa Study, Tasquinimod, Multiple Myeloma
Published: Feb 07, 2022 | Tags: BioMarin, Valoctocogene Roxaparvovec, P-III, GENEr8-1 Study, Severe Hemophilia A, EAHAD 2022
Pfizer and Valneva Report Results of VLA15 in P-II Study for the Treatment of Lyme Disease
Published: Feb 07, 2022 | Tags: Pfizer, Valneva, VLA15, P-II Study, Lyme Disease
Published: Feb 07, 2022 | Tags: Cytokinetics, US, FDA, NDA, Omecamtiv Mecarbil, Heart Failure, Reduced, Ejection Fraction
Published: Feb 07, 2022 | Tags: CSL Behring, Etranacogene Dezaparvovec, P-III, HOPE-B Trial, Hemophilia B, EAHAD 2022
Published: Feb 07, 2022 | Tags: Sanofi, Enjaymo, sutimlimab-jome, US, FDA, Approval, Cold Agglutinin Disease
Related Post: PharmaShots Weekly Snapshots (January 31 – February 04, 2022)
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com